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INTRODUCTION
Guillain-Barre Syndrome (GBS) is a neurologic disorder 
mostly appears with acute paralysis and peripheral neural 
deficit. The symptoms are symmetrical with progressive 
severity over the time. It is common among men and its 
prevalence increases in older populations (1). Post-infec-
tious immune-mediated polyneuropathy is the most 
common form of the disease; however, several variants of 
GBS based on its clinical presentation and pathophysiologi-
cal aspects also exists. Acute motor and sensory axonal 
neuropathy (AMSAN) are one of those variants present with 
severe loss of function in both motor and sensory fibers with 
marked axonal degeneration. Various etiologies and 
pathogens have been proposed as the underlying factors 
leading to GBS (2); however, reports of GBS incidence after 
brucellosis are very rare. Here, we present a case of GBS in 
a patient under treatment of brucellosis. 
CASE PRESENTATION  
A 22-year-old male patient was presented to the emergency 
ward of our hospital with a complaint of acute weakness in 
his legs. The weakness had started two days prior to the 
admission and had progressively worsened. Upon admis-
sion, the patient was not able to stand on his feet, but was 
able to use his arms completely  without any respiratory 
difficulties. He had no history of respiratory infections or 
diarrhea before admission and mentioned no other accompa-
nying symptoms other than a recent weight loss of over 8 kg. 
Family history for diseases was unremarkable, but in the 
medical history he mentioned that he had been hospitalized 
4 months earlier due to fever, chills, nausea, vomiting, and 
weight loss. The medical records showed a diagnosis of 
acute brucellosis due to the consumption of unpasteurized 
dairy products. The patient was treated with antibiotics, like 
rifampin and doxycycline. 
    He was living in a rural area near Isfahan, a large province 
in central Iran. Upon examination, he was awake and respon-
sive. His vital signs were normal with a blood pressure of 
110 over 70 mmHg, pulse rate of 68 beats per minute, 95% 
oxygen saturation level, and 36.8˚C body temperature. 
Systemic examinations yielded no remarkable abnormalities 
except a significant proximal and distal muscle wasting in 
the lower limbs. Neurological examination of the cranial 
nerves showed to be intact. No dysarthria, dysphagia, or 
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DISCUSSION
The immune responses leading to GBS are often preceded 
by an episode of previous illness such as upper respiratory 
CONCLUSION 
The present case highlights Brucella as a possible cause of 
GBS in endemic areas, which agrees with previous reports. 
diplopia were reported by the patient. Sensory and motor 
functions of the upper limbs were normal. Touch and 
position sensation of the lower limbs were also normal, but 
motor function of both the lower limbs were limited, with a 
muscle strength ranging from one to two out of five. Muscle 
tone also decreased in both legs. Deep tendon reflexes were 
normal in the upper limbs but absent in both legs. Bilateral 
plantar reflexes were normal. There were no sensory levels 
or urinary/anal sphincter abnormalities. 
     Investigations included a normal chest X-ray and normal 
electrocardiogram along with sinus rhythm. Blood cell 
counts showed a mild decrease in white blood cells (3700 
cells/mm3) with a higher percentage of lymphocytes (53%) 
and mild thrombocytopenia (136000 cells/mm3); hemoglo-
bin levels were normal (14.9 g/dL). Liver (SGOT: 18 IU/L) 
and kidney (blood urea nitrogen: 13 mg/dL, creatinine: 0.9 
mg/dL) function profiles were normal. Thyroid function 
tests were unremarkable (TSH: 1.08 IU/mL, normal range: 
0.3-5.5; T4: 0.9 ng/dL, normal range: 0.6 – 1.6). Other 
biochemical tests including blood glucose (82 mg/dl), 
sodium (141 mEq/L), potassium (3.9 mEq/L), calcium (9.4 
mEq/L), and phosphorous (3.5 mEq/L) were all within the 
normal range. The patient had an increased creatine 
phosphokinase level of 251 IU/L, and the level of lactate 
dehydrogenase was 271 IU/L. The level of C reactive 
protein was normal (0.6 mg/dL), and the serologic tests for 
brucellosis were negative. 
   Analysis of the cerebrospinal fluid (CSF) yielded the 
following results: glucose 30 mg/dL (blood glucose 75 
mg/dL), protein 140 mg/dL, normal range: 15-45 (blood: 5.4 
g/dL), LDH 26 IU/L (blood LDH 227 IU/L), and no 
red/white blood cells. 
     Magnetic resonance imaging of the brain and spine was 
normal, and we did not find any space-occupying lesions, 
disturbances in the grey-white matter interface, cerebral 
midline shift, signs of inflammation, or CSF blockage.
Further investigation by electromyography and neural 
conduction velocity studies reported a subacute severe 
peripheral axonal sensorimotor neuropathy with greater 
severity in the lower limbs. This result suggested an acute 
motor sensory axonal neuropathy (AMSAN) or GBS with 
secondary axonal features as the underlying cause for the 
patient’s symptoms. 
     With the diagnosis of GBS, secondary to acute brucello-
sis, we conducted 8 rounds of 1 hr -long plasmapheresis 
sessions for the patient. His weakness subsided gradually 
and functional activities of his legs resumed. He did not 
develop any new symptoms during the course of treatment. 
He was discharged with an improvement in his general 
conditions and followed up regularly. He remained 
symptom-free with minor weakness in his legs and was 
referred to a rehabilitation clinic for further treatments.
tract infections and gastroenteritis. The pathogens responsi-
ble for GBS include mycoplasma, cytomegalovirus, 
Ebstein-Barr virus, vaccinia, Campylobacter, varicella, 
measles, mumps, influenza, and type A and B hepatitis; 
however, there have been few reports of Brucella as a cause 
of GBS (3). Active brucellosis usually affects the gastrointes-
tinal, hepatobiliary, and skeletal muscles during the course 
of the disease; nervous system involvement is not a common 
outcome of the disease (4). 
     While some studies claim the prevalence of neuro-brucel-
losis to be 3% to 25% among the patients with brucellosis 
(4), others report only 1.7% of the cases having symptoms of 
nervous system involvement. Brucellosis can affect both 
central and peripheral nervous system manifesting various 
symptoms including headaches, meningoencephalitis and 
encephalopathy, papilledema, and inflammatory demyelinat-
ing syndromes. GBS is reported to be an  uncommon compli-
cation of this disease. In a study by Elzein et al., out of 1028 
cases of active brucellosis, 58 patients had symptoms of 
nervous system involvement; only two of these patients 
were positively diagnosed with GBS (5). 
    The Brucella-induced GBS may present as simple periph-
eral demyelination of neurons or involve axons and cause 
polyneuropathy with axonal damage. In a report by Garcia et 
al., both types of GBS were observed in patients with 
neuro-brucellosis; however, axonal damage was accompa-
nied by less favorable outcomes and worse prognosis after 
treatment (6). In contrast, Montalvo et al. reported a case of 
GBS during acute brucellosis with pure axonopathy that 
responded well to antimicrobial and plasmapheresis 
treatments (7). 
     Brucella canis and Brucella melitansis have been reported 
as the underlying agent for GBS previously(8, 9); however, 
in a study by Watanabe et al., a molecular resemblance was 
found between the lipopolysaccharide of Brucella melitansis 
and the GM-1 ganglioside. Anti-GM-1 antibodies showed 
high affinity for surface molecules in Brucella melitansis. 
Interestingly, when immunized with Brucella melitansis, the 
immunized mice showed a significant cross-reaction with 
the GBS-related Campylobacter jejuni. Moreover, the serum 
levels of anti-GM-1 antibodies were significantly higher in 
the samples infected with Brucella melitansis compared to 
those immunized with Campylobacter jejuni, indicating a 
stronger immune response to Brucella melitansis (10).
     In contrast to all the cases reported GBS during the acute 
course of brucellosis, our report presented a case with a 
history of brucellosis and signs of nervous system involve-
ment after proper anti-microbial treatments. He had a history 
of  delayed GBS along with the nervous system involvement 
included axonal damage. In addition to the previous antimi-
crobial treatment, plasmapheresis usage resulted in a satisfac-
tory outcome despite the presence of axonopathy. 
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Furthermore, we showed that the patients could be affected 
by GBS even after the acute illness is treated with antimicro-
bial agents and late onset of nervous system involvement is 
a probability that should be kept in mind.
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